Frances Hackman

873 total citations
9 papers, 239 citations indexed

About

Frances Hackman is a scholar working on Infectious Diseases, Physiology and Immunology and Allergy. According to data from OpenAlex, Frances Hackman has authored 9 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 3 papers in Physiology and 3 papers in Immunology and Allergy. Recurrent topics in Frances Hackman's work include Allergic Rhinitis and Sensitization (3 papers), Asthma and respiratory diseases (3 papers) and HIV/AIDS drug development and treatment (3 papers). Frances Hackman is often cited by papers focused on Allergic Rhinitis and Sensitization (3 papers), Asthma and respiratory diseases (3 papers) and HIV/AIDS drug development and treatment (3 papers). Frances Hackman collaborates with scholars based in United Kingdom, United States and Belgium. Frances Hackman's co-authors include John D. Davis, Richard Allan, Gary Layton, Sima S. Toussi, Eugene P. Kadar, Ravi Shankar Prasad Singh, Arthur Bergman, Lien Van Eyck, F.A. Romero and Haihong Shi and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Clinical Pharmacology & Therapeutics and AIDS.

In The Last Decade

Frances Hackman

9 papers receiving 234 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frances Hackman United Kingdom 8 118 50 47 41 33 9 239
Sara Asimus Sweden 10 47 0.4× 37 0.7× 8 0.2× 53 1.3× 5 0.2× 20 267
Gill Pearce United States 3 182 1.5× 21 0.4× 13 0.3× 12 0.3× 126 3.8× 3 375
Susan A. Iliff United States 9 88 0.7× 72 1.4× 7 0.1× 23 0.6× 166 5.0× 12 376
Andrea Witteck Switzerland 6 143 1.2× 44 0.9× 9 0.2× 18 0.4× 22 0.7× 6 340
William D. Ju United States 6 100 0.8× 39 0.8× 4 0.1× 25 0.6× 64 1.9× 7 248
N.T. On United Kingdom 6 61 0.5× 41 0.8× 3 0.1× 67 1.6× 16 0.5× 7 417
Sadeep Medhasi Thailand 10 29 0.2× 39 0.8× 3 0.1× 13 0.3× 4 0.1× 16 264
Aleksandrs Odinecs United States 8 74 0.6× 42 0.8× 1 0.0× 18 0.4× 44 1.3× 11 231
I Jiménez‐Nácher Spain 7 247 2.1× 30 0.6× 4 0.1× 8 0.2× 149 4.5× 12 371
Wirawan Adikusuma Indonesia 10 65 0.6× 83 1.7× 23 0.6× 7 0.2× 64 296

Countries citing papers authored by Frances Hackman

Since Specialization
Citations

This map shows the geographic impact of Frances Hackman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frances Hackman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frances Hackman more than expected).

Fields of papers citing papers by Frances Hackman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frances Hackman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frances Hackman. The network helps show where Frances Hackman may publish in the future.

Co-authorship network of co-authors of Frances Hackman

This figure shows the co-authorship network connecting the top 25 collaborators of Frances Hackman. A scholar is included among the top collaborators of Frances Hackman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frances Hackman. Frances Hackman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Singh, Ravi Shankar Prasad, Gregory S. Walker, Eugene P. Kadar, et al.. (2022). Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development. Clinical Pharmacology & Therapeutics. 112(6). 1201–1206. 15 indexed citations
2.
Singh, Ravi Shankar Prasad, Sima S. Toussi, Frances Hackman, et al.. (2022). Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir. Clinical Pharmacology & Therapeutics. 112(1). 101–111. 90 indexed citations
3.
Zhu, Tong, Sylvester Pawlak, Sima S. Toussi, et al.. (2022). Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF‐07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS‐CoV‐2, in Healthy Adult Participants. Clinical Pharmacology in Drug Development. 11(12). 1382–1393. 9 indexed citations
4.
North, Michelle L., Lisa M. Steacy, Richard Allan, et al.. (2014). Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit. Allergy Asthma and Clinical Immunology. 10(1). 33–33. 17 indexed citations
5.
North, Michelle L., Terry Walker, Lisa M. Steacy, et al.. (2014). Double blind randomized crossover trial of PF-03654764+fexofenadine in the environmental exposure unit (EEU). Allergy Asthma and Clinical Immunology. 10(S1). 3 indexed citations
6.
Stokes, Jeffrey R., F.A. Romero, Richard Allan, et al.. (2011). The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. Journal of Allergy and Clinical Immunology. 129(2). 409–412.e2. 41 indexed citations
7.
Davis, John D., Frances Hackman, Drew Lewis, et al.. (2010). Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clinical Therapeutics. 32(11). 1889–1895. 7 indexed citations
8.
Fätkenheuer, Gerd, Schlomo Staszewski, Frances Hackman, et al.. (2009). Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS. 23(16). 2115–2122. 34 indexed citations
9.
Davis, John D., et al.. (2008). Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. British Journal of Clinical Pharmacology. 65(s1). 68–75. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Asimus Breakdown of academic impact, for papers by Gill Pearce Breakdown of academic impact, for papers by Susan A. Iliff Breakdown of academic impact, for papers by Andrea Witteck Breakdown of academic impact, for papers by William D. Ju Breakdown of academic impact, for papers by N.T. On Breakdown of academic impact, for papers by Sadeep Medhasi Breakdown of academic impact, for papers by Aleksandrs Odinecs Breakdown of academic impact, for papers by I Jiménez‐Nácher Breakdown of academic impact, for papers by Wirawan Adikusuma
Rankless by CCL
2026